Failure to leverage outside innovation may seem inefficient, but it may be fatal over the long term for organizations that do not prudently use this strategy. Interactions with other people tend...
In some situations, filing IP very early in the invention cycle can actually do harm and perhaps kill the potential commercial prospects for an invention. Earlier blogs in this series have...
Focus on the effect you wish your IP to have, not on the IP itself. On many occasions during IP strategy training courses I have given, I have suggested that patent...
Ever made a prediction that was utterly, completely and hopelessly wrong? That’s Claim Chowder. Daring Fireball has the example of Steve Balmer’s April 2007 quote – “There’s no chance that the...
What is the value of outsourcing for an IP department manager? For many IP departments I have worked with, the value of outsourcing is calculated in terms of money saved. If...
Australia is not really leading the world in IP Strategy. However, there’s some incredibly talented people doing some great things there. For those working in the area, I was involved in...
Open Book Publishers reached out to me earlier this week to let me knowabout one of their new publications: Privilege and Property, Essays on the History of Copyright, edited by Ronan...
Looking forward to rounding off IPBC 2009 at the ‘meet the bloggers’ gathering at 5pm on 23 June at the famous Billy Goat Tavern in downtown Chicago. Thanks to David Donoghue...
Worth a read in this issue are results of the recent survey conducted by CPA and David Herrington’s article on branding in American Banks. 3 interesting things were: (1) Francis Gurry’s...
Shamnad Basheer, Duncan Bucknell and Nicholas Gruen discuss Pharmaceutical patent extensions, TRIPS, Free Trade Agreements and Pharmaceutical Manufacture for Export.
You must be logged in to post a comment.